Pharming (PHAR) Operating Leases (2019 - 2024)
Historic Operating Leases for Pharming (PHAR) over the last 6 years, with Q4 2024 value amounting to $29.9 million.
- Pharming's Operating Leases fell 968.81% to $29.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $29.9 million, marking a year-over-year decrease of 968.81%. This contributed to the annual value of $29.9 million for FY2024, which is 968.81% down from last year.
- Per Pharming's latest filing, its Operating Leases stood at $29.9 million for Q4 2024, which was down 968.81% from -$5.6 million recorded in Q2 2024.
- Over the past 5 years, Pharming's Operating Leases peaked at $33.3 million during Q4 2022, and registered a low of -$5.6 million during Q2 2024.
- Its 5-year average for Operating Leases is $11.9 million, with a median of $9.9 million in 2020.
- In the last 5 years, Pharming's Operating Leases surged by 11094.37% in 2021 and then crashed by 2826.65% in 2023.
- Quarter analysis of 5 years shows Pharming's Operating Leases stood at $9.9 million in 2020, then soared by 110.94% to $20.9 million in 2021, then soared by 59.56% to $33.3 million in 2022, then dropped by 0.56% to $33.1 million in 2023, then decreased by 9.69% to $29.9 million in 2024.
- Its Operating Leases stands at $29.9 million for Q4 2024, versus -$5.6 million for Q2 2024 and $33.1 million for Q4 2023.